1. Home
  2. TYRA vs SERV Comparison

TYRA vs SERV Comparison

Compare TYRA & SERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TYRA
  • SERV
  • Stock Information
  • Founded
  • TYRA 2018
  • SERV 2017
  • Country
  • TYRA United States
  • SERV United States
  • Employees
  • TYRA N/A
  • SERV N/A
  • Industry
  • TYRA Biotechnology: Pharmaceutical Preparations
  • SERV Industrial Specialties
  • Sector
  • TYRA Health Care
  • SERV Consumer Discretionary
  • Exchange
  • TYRA Nasdaq
  • SERV Nasdaq
  • Market Cap
  • TYRA 844.2M
  • SERV 795.0M
  • IPO Year
  • TYRA 2021
  • SERV N/A
  • Fundamental
  • Price
  • TYRA $22.01
  • SERV $10.03
  • Analyst Decision
  • TYRA Strong Buy
  • SERV Buy
  • Analyst Count
  • TYRA 5
  • SERV 4
  • Target Price
  • TYRA $31.20
  • SERV $18.33
  • AVG Volume (30 Days)
  • TYRA 448.1K
  • SERV 5.7M
  • Earning Date
  • TYRA 11-05-2025
  • SERV 11-12-2025
  • Dividend Yield
  • TYRA N/A
  • SERV N/A
  • EPS Growth
  • TYRA N/A
  • SERV N/A
  • EPS
  • TYRA N/A
  • SERV N/A
  • Revenue
  • TYRA N/A
  • SERV $1,944,483.00
  • Revenue This Year
  • TYRA N/A
  • SERV $133.16
  • Revenue Next Year
  • TYRA N/A
  • SERV $795.05
  • P/E Ratio
  • TYRA N/A
  • SERV N/A
  • Revenue Growth
  • TYRA N/A
  • SERV 15.76
  • 52 Week Low
  • TYRA $6.42
  • SERV $4.66
  • 52 Week High
  • TYRA $22.68
  • SERV $24.35
  • Technical
  • Relative Strength Index (RSI)
  • TYRA 83.81
  • SERV 43.57
  • Support Level
  • TYRA $14.84
  • SERV $8.02
  • Resistance Level
  • TYRA $22.68
  • SERV $9.91
  • Average True Range (ATR)
  • TYRA 1.57
  • SERV 0.81
  • MACD
  • TYRA 0.71
  • SERV 0.06
  • Stochastic Oscillator
  • TYRA 94.18
  • SERV 63.07

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About SERV Serve Robotics Inc. Common Stock

Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.

Share on Social Networks: